List of Lamictal Odt drug patents

Lamictal Odt is owned by Glaxosmithkline Llc.

Lamictal Odt contains Lamotrigine.

Lamictal Odt has a total of 3 drug patents out of which 0 drug patents have expired.

Lamictal Odt was authorised for market use on 08 May, 2009.

Lamictal Odt is available in tablet, orally disintegrating;oral dosage forms.

Lamictal Odt can be used as lamictal is an antiepileptic drug (aed) indicated for: epilepsy-adjunctive therapy in patients greater than or equal to 2 years of age: (1.1) partial seizures primary generalized tonic-clonic seizures.

The generics of Lamictal Odt are possible to be released after 04 January, 2029.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US7919115 GLAXOSMITHKLINE LLC Orally disintegrating tablet compositions of lamotrigine
Jan, 2029

(5 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8840925 GLAXOSMITHKLINE LLC Orally disintegrating tablet compositions of lamotrigine
Jul, 2028

(5 years from now)

US9339504 GLAXOSMITHKLINE LLC Orally disintegrating tablet compositions of lamotrigine
Jul, 2028

(5 years from now)

Drugs and Companies using LAMOTRIGINE ingredient

Market Authorisation Date: 08 May, 2009

Treatment: Lamictal is an antiepileptic drug (aed) indicated for: epilepsy-adjunctive therapy in patients greater than or equal to 2 years of age: (1.1) partial seizures primary generalized tonic-clonic seizures

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

How can I launch a generic of LAMICTAL ODT before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic